Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX)

CUSIP: 47103J105

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 7 signals
Share change
+2,356,283
Put/Call ratio
25%
SEC-reported price per share
$27.00
Indexed holders
179
Value change
-$17,647,630
Number of buys
114
Open additional details 1 more signal available
Number of sells
95
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
61,173,786

Security key

47103J105

Report period

Q1 2025

Indexed institutions

179

Top holders

10

Ownership snapshot

Top reported holders of JANX - Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
1/15
Latest evidence
31 Dec 2024
13F 13D/G 3/4/5 Lead comparable stake: 20% 14 rows are not safely comparable across share classes. 13D/G row: RA CAPITAL MANAGEMENT, L.P. Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 20%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership Top 1
RA CAPITAL MANAGEMENT, L.P. 20%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RA CAPITAL MANAGEMENT, L.P.
13F 13D/G
Company
20%
Reported 13D/G · 06 Mar 2025
$554,977,008
10,365,652 shares
— 31 Dec 2024
Avalon Ventures XI, L.P.
3/4/5
10%+ Owner
—
mixed-class rows
$346,500,118
7,383,837 shares
mixed-class rows
— 16 Oct 2024
Jay B. Lichter
3/4/5
10%+ Owner
—
mixed-class rows
$293,610,026
6,568,498 shares
mixed-class rows
— 13 Sep 2024
Bregua Corp
3/4/5
10%+ Owner
—
denominator unverified
$22,008,098
3,749,250 shares
— 15 Jun 2021
Tighe Reardon
3/4/5
Acting Chief Financial Officer
—
mixed-class rows
$227,140,231
4,305,680 shares
mixed-class rows
— 03 Jun 2024
Janus Henderson Group Ltd.
13F
Company
13F
—
denominator unverified
$190,617,226
3,562,402 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
179
Shares
66,482,175
Indexed holders
179
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 indexed holders
213
Q1 2025 indexed holders
179
Indexed holder difference
-34
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 value Q1 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .